Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | May 31, 2017 | June 02, 2017 |
| KINETA, INC./DEYMTX · Entity 77778 | Director · Executive Chair | April 01, 2021 | April 02, 2021 |
| MCKESSON CORPMCK · Entity 2904 | Director | August 17, 2020 | August 19, 2020 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Comm. Ops. | July 20, 2005 | July 22, 2005 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date May 31, 2017 · Filed June 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31 | Direct | 15,000 |
Reported balance
After 2017-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-31 · Grant · Acquired 15,000 · Balance 15,000 F1: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017.
KINETA, INC./DE
Report date April 01, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2031-03-31 | Direct | 78,650 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 78,650 · Balance 78,650 F1: This option shall vest and become exercisable in 48 equal monthly installments over four years following February 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 48 equal monthly installments over four years following February 1, 2021.
MCKESSON CORP
Report date August 17, 2020 · Filed August 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-17 transaction · row 1
1 source rowRow 1 · 2020-08-17 · Sale · Disposed 2,453 · Balance 0 |
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,714 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 1,714 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
VERTEX PHARMACEUTICALS INC / MA
Report date July 20, 2005 · Filed July 22, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2015-07-19 | Direct | 272,328 |
Reported balance
After 2005-07-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2005-07-20 · Grant · Acquired 18,000 · Balance 272,328 F1: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005. |
Filing footnotes · ownership attribution and instrument terms
F1: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 15,638 · Balance 10,290 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,290 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 4,809,418 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-01 · Disposition to issuer · Disposed 46,322 · Balance 0 F4: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F4: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2022 Filed Dec 13, 2022 16:44 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 50,000 | $3.50 | $175,000.00 |
DisclosureSEC source: 0000899243-22-038323 · doc4.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director · CEO and Chairperson 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F2 · balance_after: Includes 2,704 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021 and June 30, 2022. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,216 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · derivative · entry 13 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,145 Underlying: Common Stock · 2,216 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · derivative · entry 12 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 602 | $584.57 | $351,911.14 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 11 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,093 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,045 | $583.16 | $609,402.20 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 10 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 1,045 shares of Company stock on September 6, 2022 at prices ranging from $583.00 to $583.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,220 | $582.56 | $710,723.20 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 9 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,740 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 1,220 shares of Company stock on September 6, 2022 at prices ranging from $582.31 to $582.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 822 | $581.44 | $477,943.68 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 8 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,960 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 822 shares of Company stock on September 6, 2022 at prices ranging from $581.08 to $581.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 688 | $580.44 | $399,342.72 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 7 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,782 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: epresents volume-weighted average price of sales of 688 shares of Company stock on September 6, 2022 at prices ranging from $580.12 to $580.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 550 | $579.85 | $318,917.50 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 6 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,470 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 550 shares of Company stock on September 6, 2022 at prices ranging from $579.00 to $579.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 273 | $578.25 | $157,862.25 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 5 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,020 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 273 shares of Company stock on September 6, 2022 at prices ranging from $578.00 to $578.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $577.07 | $288,535.00 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 4 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,293 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on September 6, 2022 at prices ranging from $577.00 to $577.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,784 | $371.40 | $1,405,377.60 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $576.73 | $173,019.00 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,009 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on September 6, 2022 at prices ranging from $576.34 to $576.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,216 | $374.12 | $829,049.92 |
DisclosureSEC source: 0001883850-22-000063 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 425,772 | $0.00 Strike: $30.36 | $0.00 |
DisclosureSEC source: 0000899243-22-005938 · doc4.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director · CEO and Chairperson 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,772 Underlying: Common Stock · 425,772 shares Expires 2032-02-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001883850-22-000007 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000007 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,093 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,909 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · derivative · entry 17 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,909 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,039 | $0.00 Strike: $345.47 | $0.00 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · derivative · entry 16 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,039 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,174 | $664.32 | $779,911.68 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 15 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 1,174 shares of Company stock on September 15, 2021 at prices ranging from $664.00 to $664.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 905 | $663.73 | $600,675.65 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 14 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,076 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 905 shares of Company stock on September 15, 2021 at prices ranging from $663.15 to $663.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $662.55 | $1,987.65 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 13 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,981 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,344 | $661.56 | $2,212,256.64 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 12 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3,344 shares of Company stock on September 15, 2021 at prices ranging from $661.02 to $661.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 448 | $660.78 | $296,029.44 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 11 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,328 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 448 shares of Company stock on September 15, 2021 at prices ranging from $660.29 to $660.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $659.00 | $197,700.00 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 10 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,776 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 935 | $658.65 | $615,837.75 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 9 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,076 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 835 | $657.53 | $549,037.55 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 8 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,011 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,400 | $656.48 | $919,072.00 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 7 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,846 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 1,400 shares of Company stock on September 15, 2021 at prices ranging from $656.18 to $656.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 403 | $655.14 | $264,021.42 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 6 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,246 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 403 shares of Company stock on September 15, 2021 at prices ranging from $655.14 to $655.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $653.31 | $522,648.00 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 5 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,649 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on September 15, 2021 at prices ranging from $653.11 to $653.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,101 | $652.95 | $718,897.95 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 4 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,449 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 1,101 shares of Company stock on September 15, 2021 at prices ranging from $652.48 to $652.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $651.36 | $195,408.00 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,550 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,039 | $345.47 | $1,740,823.33 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 6,909 | $380.95 | $2,631,983.55 |
DisclosureSEC source: 0001237899-21-000022 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,100 | $0.00 Strike: $345.47 | $0.00 |
DisclosureSEC source: 0001708138-21-000061 · edgardoc.xml · derivative · entry 6 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,039 Underlying: Common Stock · 5,100 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,100 | $650.00 | $3,315,000.00 |
DisclosureSEC source: 0001708138-21-000061 · edgardoc.xml · nonDerivative · entry 4 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,100 | $345.47 | $1,761,897.00 |
DisclosureSEC source: 0001708138-21-000061 · edgardoc.xml · nonDerivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 900 | $0.00 Strike: $345.47 | $0.00 |
DisclosureSEC source: 0001708138-21-000061 · edgardoc.xml · derivative · entry 5 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,139 Underlying: Common Stock · 900 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $650.00 | $585,000.00 |
DisclosureSEC source: 0001708138-21-000061 · edgardoc.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 900 | $345.47 | $310,923.00 |
DisclosureSEC source: 0001708138-21-000061 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $345.47 | $0.00 |
DisclosureSEC source: 0001708138-21-000052 · edgardoc.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,039 Underlying: Common Stock · 2,000 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $625.00 | $1,250,000.00 |
DisclosureSEC source: 0001708138-21-000052 · edgardoc.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $345.47 | $690,940.00 |
DisclosureSEC source: 0001708138-21-000052 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 78,650 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0000899243-21-014638 · doc4.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,650 Underlying: Common Stock · 78,650 shares Expires 2031-03-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 equal monthly installments over four years following February 1, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:47 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 732,714 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000899243-21-005097 · doc4.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,714 Underlying: Common Stock · 732,714 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 18:36 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantCommon Stock | 1,118 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004739 · doc4.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,008 F1 · kind: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on February 1, 2022. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001708138-21-000007 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000007 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 19:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantWarrant (Right to Buy) · Derivative | 6,038 | Not disclosed Strike: $24.05 | Not disclosed |
DisclosureSEC source: 0000899243-20-035259 · doc4.xml · derivative · entry 5 COLES N ANTHONY · CIK 0001197018 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,038 Underlying: Common Stock · 6,038 shares Expires 2025-08-14 F1 · date: On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. F8 · price: Received in the Merger in exchange for a warrant to purchase 28,642 shares of Yumanity, Inc. common stock for $5.069 per share. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 19:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 12,082 | Not disclosed Strike: $8.16 | Not disclosed |
DisclosureSEC source: 0000899243-20-035259 · doc4.xml · derivative · entry 4 COLES N ANTHONY · CIK 0001197018 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,082 Underlying: Common Stock · 12,082 shares Expires 2029-09-09 F1 · date: On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. F7 · price: Received in the Merger in exchange for a stock option to acquire 57,307 shares of Yumanity, Inc. common stock for $1.72 per share. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on December 4, 2019. The remaining 75% vest in equal monthly installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.